

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June, 2022.

Commission File Number: **001-40673**

**Cybin Inc.**

(Exact Name of Registrant as Specified in Charter)

**100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

**INCORPORATION BY REFERENCE**

Exhibit 99.1 of this Form 6-K of Cybin Inc. (the "Company") is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-259994) of the Company, as amended or supplemented.



**EXHIBIT INDEX**

99.1 [News Release dated June 3, 2022](#)



## Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program

**TORONTO, CANADA** – June 3, 2022 – [Cybin Inc. \(NEO:CYBN\) \(NYSE American:CYBN\)](#) (“**Cybin**” or the “**Company**”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced the team of 28 esteemed faculty and advisors who will lead the Company’s EMBARK Psychedelic Facilitator Training Program. Recognizing the crucial importance of supporting psychedelic study facilitators with quality training, Cybin has brought together recognized leaders and senior psychedelic-assisted psychotherapy trainers from leading universities and psychedelic research and training organizations.

“For EMBARK, we have set out to build an extraordinary training program in psychedelic-assisted psychotherapy. We don’t think a single person holds all the answers. Instead, we have gathered together the wisdom of 28 of the world’s leading experts in psychedelic practice as teachers, supervisors, and advisors for our program. They are the recognized leaders in their fields, and I’m deeply grateful for their skill, integrity, and heartfelt teachings,” said Dr. Alex Belser, Chief Clinical Officer at Cybin.

[EMBARK](#) is a leading-edge model of psychedelic-assisted psychotherapy co-developed by Alex Belser, PhD, and Bill Brennan, PhD. EMBARK provides six clinical domains (**E**xistential-Spiritual, **M**indfulness, **B**ody Aware, **A**ffective-Cognitive, **R**elational, and **K**eeping Momentum). Additionally, EMBARK is built upon four care cornerstones: trauma-informed care, culturally-informed care, ethically rigorous care, and collective care.

“Because of the multi-dimensional, profound content of psychedelic-assisted psychotherapy sessions, a training to prepare therapists to do this work requires more ethical education than what is offered by the traditional, stand-alone ethics lecture. Cybin’s EMBARK accepted that challenge and created a program in which ethical inquiry undergirds all of its programming,” said Kylea Taylor, LMFT, author of *The Ethics of Caring* and creator of InnerEthics®.

### **EMBARK faculty members include:**

- **Anthony Back, MD**, Professor of Medicine at the University of Washington in Seattle, and the Fred Hutchinson Cancer Research Center. He is the Principal Investigator for a Phase 2 clinical trial to treat frontline clinicians experiencing COVID-related burnout and distress.
- **Alex Belser, PhD**, co-creator of EMBARK, Chief Clinical Officer at Cybin, Chair of Cybin's Clinical Advisory Board, and Co-Investigator on a psilocybin clinical trial at Yale University.
- **Bill Brennan, PhD**, co-creator of EMBARK and author researching best practices for psychedelic psychotherapy.
- **NiCole T. Buchanan, PhD**, Clinical-Community Psychologist, Professor, and Justice, Equity, Diversity, and Inclusion (JEDI) consultant.
- **Stacia Butterfield**, certified Holotropic Breathwork practitioner and a teacher with Grof Transpersonal Training.
- **Jeffrey Guss, MD**, psychiatrist, psychoanalyst, researcher and teacher specializing in psychoanalytic therapy and psychedelic therapy. He is a Lead Trainer at Fluence and Clinical Assistant Professor of Psychiatry at the NYU School of Medicine.
- **Amir Inamdar, MBBS, DNB (Psych), MFPM**, psychiatrist, pharmaceutical physician, drug developer and Cybin's Chief Medical Officer.
- **Alex Kelman, PhD**, Senior Director for the EMBARK Training Program and Attending Psychologist and Assistant Clinical Professor at the University of California, Los Angeles.
- **Adele Lafrance, PhD**, developer of emotion-focused treatment modalities, and Strategic Lead and Clinical Investigator for MDMA-Assisted Therapy Research
- **Manuela Mischke-Reeds, MA, MFT**, somatic psychotherapist and teacher, co-director of the Hakomi Institute of California, Chief Mental Health Officer at Abroad.
- **Marcela Ot'alora, G, MA, LPC**, trainer, researcher and advocate for the safe and ethical use of psychedelic therapy. She is a lead trainer for the MAPS MDMA Therapy Training Program.
- **Florie St. Aime, LCSW**, invites others into liberation practices through social justice organizing, group facilitation, individual psychotherapy, supervision and holding sacred space.
- **Kylea Taylor, MFT**, created and teaches InnerEthics®, a self-reflective approach to ethics education that she first described in her book *The Ethics of Caring*.

### **Advisors, Clinical Supervisors, and Subject Matter Experts include:**

- **Melissa Field**, Senior Manager of Clinical Process and Training at Cybin.
- **Ingmar Gorman, PhD**, CEO and Co-Founder of Fluence, a clinical psychologist, and former site Co-Principal Investigator and therapist for MAPS MDMA-assisted psychotherapy trials.
- **Charlotte Harrison**, clinical trial consultant collaborating with the Cybin team on protocol and training development. She has worked in clinical research for over a decade, including overseeing MAPS' MDMA-assisted psychotherapy program.

- **Diane Hollman**, Senior Director of Clinical Alliances at Cybin.
- **Franklin King, MD**, Instructor at Harvard Medical School and psychiatrist at Massachusetts General Hospital where he serves as the Director of Training and Education at the Center for Neuroscience of Psychedelics.
- **Robert Krause, DNP APRN-BC**, Co-director of Centered PLLC, researcher, therapist, and educator. He has lectured at Yale University and is visiting faculty in the Consciousness Studies Department at the Graduate Institute. A graduate of CIIS's founding cohort in Psychedelic Assisted Therapy, he is also a MAPS therapist in an expanded access protocol.
- **John Krystal, MD**, Chair at Yale University's Department of Psychiatry and Co-Director of Yale's Center for Clinical Investigation.
- **Dennis McKenna, PhD**, author or co-author of three books and over 50 peer-reviewed papers on the chemistry, ethnopharmacology, and neuroscience of psychedelics, as well as other botanical medicines. He is a founding board member of Heffter Research Institute, and the founder and President of the McKenna Academy of Natural Philosophy, which is focused on psychedelic education and the preservation of traditional knowledge, facilitating its integration with scientific knowledge.
- **Elizabeth Nielson, PhD**, CVO and Co-Founder of Fluence, a site Co-Principal Investigator and therapist for MAPS MDMA-assisted psychotherapy trials, and an investigator in NYU's study of psilocybin-assisted psychotherapy for Alcohol Use Disorder.
- **Sarah Scheld, MA**, EMBARK Training Program Consultant.
- **Jordan Slosower, MD, MSc**, psychiatrist and researcher at Yale University where he serves as an investigator and therapist in several clinical trials of psilocybin-assisted therapy. Jordan is also a clinical investigator in MAPS' Expanded Access Program for MDMA-assisted therapy of PTSD and serves as a lead trainer with Usona Institute's psilocybin facilitator training program.
- **Andrew Solomon, PhD**, professor of clinical psychology at Columbia and a lecturer in psychiatry at Yale, is the National Book Award-winning author of *The Noonday Demon* and *Far from the Tree*, a writer for *The New Yorker*, and a writer and speaker on politics, psychology, and the arts.

**Cybin's Clinical Advisory Board includes:**

- **Anthony Back, MD**, Professor of Medicine at the University of Washington School of Medicine in Seattle and the Fred Hutchinson Cancer Research Center. He is the Principal Investigator for a Phase 2 clinical trial to treat frontline clinicians experiencing COVID-related burnout and distress.
- **Alex Belser, PhD**, Chief Clinical Officer at Cybin and Chair of Cybin's Clinical Advisory Board.
- **Maurizio Fava, MD**, Psychiatrist-in-Chief in the Department of Psychiatry at Massachusetts General Hospital, and an Associate Dean for Clinical and Translational Research at Harvard Medical School.

- **Tom Laughren, MD**, Director at Laughren Psychopharm Consulting, LLC, and the Former Director of FDA's Division of Psychiatry Products.
- **Lynn Marie Morski, MD, JD**, President of the Psychedelic Medicine Association.

[Cybin launched the EMBARK Psychedelic Facilitator Training Program](#) for study facilitators in October 2021. The program offers psychedelic clinical trial facilitators the foundational training needed to provide skillful and ethical care to treat participants receiving psychedelic-assisted therapy. The curriculum prepares facilitators to work with a range of experiences that may arise for participants in each domain, and to ground their work in each care cornerstone.

For more information on the EMBARK program, please click [here](#).

### **About Cybin**

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

### **Cautionary Notes and Forward-Looking Statements**

Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin's future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Company's proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to potentially treat psychiatric disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets

where the Company operates; and the risk factors set out in the Company's management's discussion and analysis for the period ended December 31, 2021 and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on [www.sedar.com](http://www.sedar.com) and with the U.S. Securities and Exchange Commission on EDGAR at [www.sec.gov](http://www.sec.gov). Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.

*Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.*

**Investor & Media Contact:**

Leah Gibson

Vice President, Investor Relations & Strategic Communications

Cybin Inc.

[irteam@cybin.com](mailto:irteam@cybin.com) – or – [media@cybin.com](mailto:media@cybin.com)